NHS-Galleri Linked to Delays - Scorecard - MDSpire

NHS-Galleri Linked to Delays

  • By

  • Andrea Surnit

  • June 4, 2026

  • 6 min

Share

Clinical Scorecard: NHS-Galleri Linked to Delays

At a Glance

CategoryDetail
Condition
Key MechanismsParticipation in the NHS-Galleri trial associated with increased diagnostic delays for certain cancers.
Target Population
Care Setting

Key Highlights

  • Modest increase in diagnostic delay rates observed in participating regions.
  • Average time to diagnostic resolution increased by about 2 days in participating regions.
  • 9,591 additional referrals experienced diagnostic delay during the first year of the trial.
  • Trial did not meet its primary endpoint of reducing combined stage III-IV cancer.

Guideline-Based Recommendations

Diagnosis

  • Monitor diagnostic delay rates in regions participating in trials.

Management

  • Consider downstream capacity needs when implementing MCED testing.

Monitoring & Follow-up

  • Evaluate the impact of trial participation on routine diagnostic services.

Risks

  • Be aware of potential harms such as false reassurance and diagnostic cascades.

Patient & Prescribing Data

Estimated nationwide rollout would cost about $19.2 billion annually for testing alone.

Clinical Best Practices

  • Assess socioeconomic factors in regions participating in trials.
  • Ensure adequate healthcare staffing in regions implementing new screening tests.

Related Resources & Content

Original Source(s)

Related Content